India to Canada: Gliclazide Export Trade Route

The India to Canada Gliclazide corridor is one of India's established pharmaceutical export routes, with 92 shipments documented worth a combined $8.2M USD. The route is dominated by MYLAN LABORATORIES LIMITED, which alone accounts for roughly 52% of all export value, reflecting the consolidated nature of India's gliclazide manufacturing sector.

Across 8 active suppliers, the average shipment value stands at $89.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (69%) and air (18%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during July–September, with an average transit time of 21 days port-to-port. The route has recorded an annual growth rate of 23.2%, placing it at rank #8 among India's top gliclazide export destinations globally.

On the import side, key buyers of Indian gliclazide in Canada include MYLAN PHARMACEUTICALS ULC, SUN PHARMA CANADA INC., MINT PHARMACEUTICALS INC and 12 others. MYLAN PHARMACEUTICALS ULC is the single largest importer with 2 shipments valued at $4.1M USD.

India's gliclazide exports to Canada are driven primarily by a handful of large-scale manufacturers. MYLAN LABORATORIES LIMITED with 6 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 8 active exporters signals a competitive but concentrated market — buyers in Canada benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — MYLAN LABORATORIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, CENTAUR PHARMACEUTICALS PRIVATE LIMITED — together account for 94% of total trade value on this route. The average shipment value of $89.0K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as gliclazide modified release tablets 60mg(gliclazide tablets 60mg) [4692 packs x100's bottles] batch no. pte4696a & pte and gliclazide modified release tablets 60mg(gliclazide tablets 60mg) [2288 packs x100's bottles] batch no. pte4695a mfg d, suggesting that buyers in Canada tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, MYLAN PHARMACEUTICALS ULC is the largest importer with 2 shipments worth $4.1M USD — representing 50% of all gliclazide imports from India on this route. A total of 15 buyers are active on this corridor.